Novartis - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Novartis’ Cosentyx sees mixed results from head-to-head with Humira

Although Novartis’ Cosentyx showed numerically higher results for its primary endpoint, it failed to demonstrate statistically significant superiority over AbbVie’s Humira.